Viatris (VTRS) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Viatris Revenue Highlights

Latest Revenue (Y)

$14.74B

Latest Revenue (Q)

$3.58B

Main Segment (Y)

Brands

Main Geography (Y)

Developed Markets Segment

Viatris Revenue by Period

Viatris Revenue by Year

Date	Revenue	Change
2024-12-31	$14.74B	-4.46%
2023-12-31	$15.43B	-5.14%
2022-12-31	$16.26B	-9.08%
2021-12-31	$17.89B	49.73%
2020-12-31	$11.95B	3.87%
2019-12-31	$11.50B	0.58%
2018-12-30	$11.43B	-3.98%
2017-12-30	$11.91B	7.50%
2016-12-30	$11.08B	17.47%
2015-12-30	$9.43B	22.15%
2014-12-30	$7.72B	11.73%
2013-12-30	$6.91B	1.01%
2012-12-31	$6.84B	11.49%
2011-12-31	$6.14B	12.61%
2010-12-31	$5.45B	6.98%
2009-12-31	$5.09B	-0.87%
2008-12-31	$5.14B	76.85%
2007-12-31	$2.91B	131.08%
2006-03-31	$1.26B	0.30%
2005-03-31	$1.25B	-8.82%
2004-03-31	$1.37B	24.51%
2002-03-31	$1.10B	30.40%
2001-03-31	$846.70M	7.16%
2000-03-31	$790.14M	9.57%
1999-03-31	$721.10M	36.42%
1998-03-31	$528.60M	20.08%
1997-03-31	$440.20M	12.04%
1996-03-31	$392.90M	-0.81%
1995-03-31	$396.10M	57.31%
1994-03-31	$251.80M	18.77%
1993-03-31	$212.00M	-

Viatris generated $14.74B in revenue during NA 2024, up -4.46% compared to the previous quarter, and up 128.16% compared to the same period a year ago.

Viatris Revenue by Quarter

Date	Revenue	Change
2025-06-30	$3.58B	10.07%
2025-03-31	$3.25B	-7.76%
2024-12-31	$3.53B	-5.62%
2024-09-30	$3.74B	-1.54%
2024-06-30	$3.80B	3.64%
2024-03-31	$3.66B	-4.53%
2023-12-31	$3.84B	-2.65%
2023-09-30	$3.94B	0.59%
2023-06-30	$3.92B	5.08%
2023-03-31	$3.73B	-3.79%
2022-12-31	$3.88B	-4.96%
2022-09-30	$4.08B	-0.94%
2022-06-30	$4.12B	-1.79%
2022-03-31	$4.19B	-3.45%
2021-12-31	$4.34B	-4.30%
2021-09-30	$4.54B	-0.90%
2021-06-30	$4.58B	3.33%
2021-03-31	$4.43B	22.27%
2020-12-31	$3.62B	21.92%
2020-09-27	$2.97B	8.82%
2020-06-28	$2.73B	4.28%
2020-03-29	$2.62B	-17.94%
2019-12-31	$3.19B	7.77%
2019-09-29	$2.96B	3.86%
2019-06-29	$2.85B	14.27%
2019-03-30	$2.50B	-18.94%
2018-12-30	$3.08B	7.56%
2018-09-29	$2.86B	1.93%
2018-06-29	$2.81B	4.61%
2018-03-30	$2.68B	-17.12%
2017-12-30	$3.24B	8.43%
2017-09-29	$2.99B	0.84%
2017-06-29	$2.96B	8.92%
2017-03-30	$2.72B	-16.78%
2016-12-31	$3.27B	6.89%
2016-09-30	$3.06B	19.39%
2016-06-30	$2.56B	16.86%
2016-03-31	$2.19B	-12.02%
2015-12-31	$2.49B	-7.59%
2015-09-30	$2.70B	13.64%
2015-06-30	$2.37B	26.71%
2015-03-31	$1.87B	-10.13%
2014-12-31	$2.08B	-0.06%
2014-09-30	$2.08B	13.43%
2014-06-30	$1.84B	7.09%
2014-03-31	$1.72B	-5.14%
2013-12-31	$1.81B	2.33%
2013-09-30	$1.77B	3.86%
2013-06-30	$1.70B	4.30%
2013-03-31	$1.63B	-4.16%
2012-12-31	$1.70B	-5.93%
2012-09-30	$1.81B	6.99%
2012-06-30	$1.69B	6.23%
2012-03-31	$1.59B	4.00%
2011-12-31	$1.53B	-2.83%
2011-09-30	$1.58B	0.12%
2011-06-30	$1.57B	8.62%
2011-03-31	$1.45B	1.01%
2010-12-31	$1.43B	5.86%
2010-09-30	$1.36B	-0.98%
2010-06-30	$1.37B	5.89%
2010-03-31	$1.29B	-4.40%
2009-12-31	$1.35B	6.94%
2009-09-30	$1.26B	-0.23%
2009-06-30	$1.27B	4.72%
2009-03-31	$1.21B	0.56%
2008-12-31	$1.20B	-27.38%
2008-09-30	$1.66B	37.71%
2008-06-30	$1.20B	11.97%
2008-03-31	$1.07B	-

Viatris generated $3.58B in revenue during Q2 2025, up 10.07% compared to the previous quarter, and up 97.78% compared to the same period a year ago.

Viatris Revenue Breakdown

Viatris Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Generics	$5.49B	$5.59B	$5.02B	-	-
Brands	$9.20B	$9.80B	$9.89B	-	-
Complex GX and Biosimilars	-	-	$1.31B	-	-
Product	-	-	$16.22B	$17.81B	-
Product and Service, Other	-	-	-	-	$126.10M

Viatris's latest annual revenue breakdown by segment (product or service), as of Dec 24: Brands (62.62%), and Generics (37.38%).

Quarterly Revenue by Product

Product/Service	Jun 25	Mar 25	Dec 24	Sep 24	Mar 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
Generics	$1.28B	$1.13B	$2.77B	$1.38B	$1.34B	$1.23B	-	-	-	-	-	-	-	-	-	-
Brands	$2.28B	$2.12B	$4.53B	$2.36B	$2.31B	$2.53B	-	-	-	-	-	-	-	-	-	-
Xalabrands	-	-	-	-	$42.50M	$47.90M	$48.40M	$54.00M	$55.80M	$58.30M	$57.90M	-	-	-	-	-
Product and Service, Other	-	-	-	-	-	-	$9.10M	$10.00M	$8.90M	$10.80M	$11.40M	$13.50M	-	-	-	-

Viatris's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Brands (64.01%), and Generics (35.99%).

Viatris Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Emerging Markets Segment	$2.26B	$2.55B	$2.62B	-	-
Japan, Australia and New Zealand Segment	$1.35B	$1.42B	$1.63B	-	-
Greater China Segment	$2.17B	$2.16B	$2.20B	-	-
Developed Markets Segment	$8.96B	$9.25B	$9.77B	-	-
UNITED STATES	-	-	$3.95B	$4.18B	$3.75B
CHINA	-	-	$1.95B	$1.98B	-
INDIA	-	-	-	-	$1.16B
FRANCE	-	-	-	-	$1.07B

Viatris's latest annual revenue breakdown by geography, as of Dec 24: Developed Markets Segment (60.80%), Emerging Markets Segment (15.34%), Greater China Segment (14.71%), and Japan, Australia and New Zealand Segment (9.16%).

Quarterly Revenue by Country

Country	Jun 25	Mar 25	Dec 24	Sep 24	Mar 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
Developed Markets Segment	$2.13B	$1.90B	$4.50B	$2.30B	$2.17B	-	-	-	-	-	-	-	-	-	-	-
Emerging Markets Segment	$556.90M	$523.10M	$1.10B	$533.20M	$626.40M	-	-	-	-	-	-	-	-	-	-	-
Greater China Segment	$588.90M	$555.50M	$1.06B	$561.80M	$543.90M	$548.40M	$1.60M	$2.20M	$100.00K	$1.90M	$1.70M	$3.40M	$2.70M	-	$1.10M	$1.00M
Japan, Australia and New Zealand Segment	$306.70M	$277.10M	$687.60M	$344.30M	$317.80M	-	-	-	-	-	-	-	-	-	-	-

Viatris's latest quarterly revenue breakdown by geography, as of Jun 25: Developed Markets Segment (59.45%), Greater China Segment (16.44%), Emerging Markets Segment (15.55%), and Japan, Australia and New Zealand Segment (8.56%).

Viatris Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
RDY	Dr. Reddy's Laboratories	$279.16B	-
VTRS	Viatris	$14.74B	$3.58B
BAX	Baxter	$4.51B	$2.81B
ELAN	Elanco Animal Health	$4.44B	$1.24B
MRNA	Moderna	$3.24B	$143.00M
EXAS	Exact Sciences	$2.76B	$811.09M
NBIX	Neurocrine Biosciences	$2.36B	$687.50M
IONS	Ionis Pharmaceuticals	$705.14M	$452.00M
BBIO	BridgeBio Pharma	$221.90M	$71.50M
ROIV	Roivant Sciences	$124.80M	$7.57M
RGC	Regencell Bioscience	-	-

VTRS Revenue FAQ

What is Viatris’s yearly revenue?

Viatris's yearly revenue for 2024 was $14.74B, representing a decrease of -4.46% compared to 2023. The company's yearly revenue for 2023 was $15.43B, representing a decrease of -5.14% compared to 2022. VTRS's yearly revenue for 2022 was $16.26B, representing a decrease of -9.08% compared to 2021.

What is Viatris’s quarterly revenue?

Viatris's quarterly revenue for Q2 2025 was $3.58B, a 10.07% increase from the previous quarter (Q1 2025), and a -5.65% decrease year-over-year (Q2 2024). The company's quarterly revenue for Q1 2025 was $3.25B, a -7.76% decrease from the previous quarter (Q4 2024), and a -11.17% decrease year-over-year (Q1 2024). VTRS's quarterly revenue for Q4 2024 was $3.53B, a -5.62% decrease from the previous quarter (Q3 2024), and a -8.06% decrease year-over-year (Q4 2023).

What is Viatris’s revenue growth rate?

Viatris's revenue growth rate for the last 3 years (2022-2024) was -9.37%, and for the last 5 years (2020-2024) was 23.38%.

What are Viatris’s revenue streams?

Viatris's revenue streams in c 24 are Generics, and Brands. Generics generated $5.49B in revenue, accounting 37.38% of the company's total revenue, down -1.71% year-over-year. Brands generated $9.2B in revenue, accounting 62.62% of the company's total revenue, down -6.12% year-over-year.

What is Viatris’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Viatris was Brands. This segment made a revenue of $9.2B, representing 62.62% of the company's total revenue.